Article Sidebar

Download
PDF

Main Article Content

Abstract

In the present study, coumarins were synthesized by reaction of substituted phenols and ethyl acetoacetate in the presence of concentrated sulphuric acid (Pechmann reaction)and substituted with different electro-positive and electronegative groups. The binding affinity of compounds was evaluated by molecular docking in the binding site of phospho-diestrase 4 (PDE4) protein using AutoDockVina and dock scores were calculated. The compounds with good binding affinity were screened for the anti-inflammatory activity using carrageenan induced rat paw edema method. Docking studies showed that compounds 3(d-k) have good binding affinity with PDE4. Further, pharmacological investigation revealed that compound 3(d-e) exhibited highest antiinflammatory activity.

Keywords

Coumarin Anti-Inflammatory Phosphodiestrase inhibitors PDE4B Docking studies

Article Details

How to Cite
Girdhar, A., Raheja, S., Pandita, D., Kharb, V., & Lather, V. (2018). Synthesis, Characterization and Biological Evaluation of Novel Coumarins as Promising Anti-Inflammatory Agents. Asian Journal of Organic & Medicinal Chemistry, 3(4), 150–154. https://doi.org/10.14233/ajomc.2018.AJOMC-P141
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. D.J. Hadjipavlou-Litina, K.E. Litinas and C. Kontogiorgis, Anti-Inflamm. Anti-Allergy Agents Med. Chem., 6, 293 (2007); https://doi.org/10.2174/187152307783219989.
  2. C.A. Kontogiorgis and D.J. Hadjipavlou-Litina, Synthesis and Anti-inflammatory Activity of Coumarin Derivatives, J. Med. Chem., 48, 6400 (2005); https://doi.org/10.1021/jm0580149.
  3. H. Pynam and S.M. Dharmesh, Antioxidant and Anti-Inflammatory Properties of Marmelosin from Bael (Aegle marmelos L.); Inhibition of TNF-a Mediated Inflammatory/Tumor Markers, Biomed. Pharmacother., 106, 98 (2018); https://doi.org/10.1016/j.biopha.2018.06.053.
  4. D. Singh, D.P. Pathak and Anjali, Coumarins: An Overview of Medicinal Chemistry, Potential for New Drug Molecules, Int. J. Pharm. Sci. Res., 7, 482 (2016); https://doi.org/10.13040/IJPSR.0975-8232.7(2).482-04.
  5. F. Borges, F. Roleira, N. Milhazes, N. Santana and E. Uriarte, Simple Coumarins and Analogues in Medicinal Chemistry: Occurrence, Synthesis and Biological Activity, Curr. Med. Chem., 12, 887 (2005); https://doi.org/10.2174/0929867053507315.
  6. M.A. Salem, M.I. Marzouk and A.M. El-Kazak, Synthesis and Charact-erization of Some New Coumarins with in vitro Antitumor and Anti-oxidant Activity and High Protective Effects against DNA Damage, Molecules, 21, 249 (2016); https://doi.org/10.3390/molecules21020249.
  7. J. Klenkar and M. Molnar, Natural and Synthetic Coumarins as Potential Anticancer Agents, J. Chem. Pharm. Res., 7, 1223 (2015).
  8. Y. Al-Majedy, A. Al-Amiery, A.A. Kadhum and A.B. Mohamad, Anti-oxidant Activity of Coumarins, Syst. Rev. Pharm., 8, 24 (2016); https://doi.org/10.5530/srp.2017.1.6.
  9. A. Behrami, Antibacterial Activity of Coumarine Derivatives Synthesized from 4-Chlorochromen-2-one: The Comparison with Standard Drug, Orient. J. Chem., 30, 1747 (2014); https://doi.org/10.13005/ojc/300433.
  10. P.R. Heckman, C. Wouters and J. Prickaerts, Phosphodiesterase Inhib-itors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview, Curr. Pharm. Des., 21, 317 (2014); https://doi.org/10.2174/1381612820666140826114601.
  11. S. Vilar, E. Quezada, L. Santana, E. Uriarte, M. Yánez, N. Fraiz, C. Alcaide, E. Cano and F. Orallo, Design, Synthesis, and Vasorelaxant and Platelet Antiaggregatory Activities of Coumarin-Resveratrol Hybrids, Bioorg. Med. Chem. Lett., 16, 257 (2006); https://doi.org/10.1016/j.bmcl.2005.10.013.
  12. G. Melagraki, A. Afantitis, O. Igglessi-Markopoulou, A. Detsi, M. Koufaki, C. Kontogiorgis and D.J. Hadjipavlou-Litina, Synthesis and Evaluation of the Antioxidant and Anti-Inflammatory Activity of Novel Coumarin-3-Aminoamides and their Alpha-Lipoic Acid Adducts, Eur. J. Med. Chem., 44, 3020 (2009); https://doi.org/10.1016/j.ejmech.2008.12.027.
  13. D.M. Manidhar, R.K. Kesharwani, N.B. Reddy, C.S. Reddy and K. Misra, Designing, Synthesis, and Characterization of Some Novel Coumarin Derivatives as Probable Anticancer Drugs, Med. Chem. Res., 22, 4146 (2013); https://doi.org/10.1007/s00044-012-0299-0.
  14. P.M. Ronad, M.N. Noolvi, S. Sapkal, S. Dharbhamulla and V.S. Maddi, Synthesis and Antimicrobial Activity of 7-(2-Substituted Phenylthiazo-lidinyl)benzopyran-2-one Derivatives, Eur. J. Med. Chem., 45, 85 (2010); https://doi.org/10.1016/j.ejmech.2009.09.028.
  15. M. Ghate, R.A. Kusanur and M.V. Kulkarni, Synthesis and in vivo Analgesic and Anti-inflammatory Activity of Some Bi Heterocyclic Coumarin Derivatives, Eur. J. Med. Chem., 40, 882 (2005); https://doi.org/10.1016/j.ejmech.2005.03.025.
  16. J.C. Trivedi, J.B. Bariwal, K.D. Upadhyay, Y.T. Naliapara, S.K. Joshi, C.C. Pannecouque, E. De Clercq and A.K. Shah, Improved and Rapid Synthesis of New Coumarinyl Chalcone Derivatives and their Antiviral Activity, Tetrahedron Lett., 48, 8472 (2007); https://doi.org/10.1016/j.tetlet.2007.09.175.
  17. R. Minhas, S. Sandhu, Y. Bansal and G. Bansal, Benzoxazole-Coumarin Derivatives: Potential Candidates for Development of Safer Anti-inflammatory Drugs, Der Chem. Sinica, 8, 146 (2017).
  18. M.D. Houslay, P. Schafer and K.Y.J. Zhang, Keynote Review: Phospho-diesterase-4 as a Therapeutic Target, Drug Discov. Today, 10, 1503 (2005); https://doi.org/10.1016/S1359-6446(05)03622-6.
  19. P.S. Govek, G. Oshiro, J.V. Anzola, C. Beauregard, J. Chen, A.R. Coyle, D.A. Gamache, M.R. Hellberg, J.N. Hsien, J.M. Lerch, J.C. Liao, J.W. Malecha, L.M. Staszewski, D.J. Thomas, J.M. Yanni, S.A. Noble and A.K. Shiau, Water-Soluble PDE4 Inhibitors for the Treatment of Dry Eye, Bioorg. Med. Chem. Lett., 20, 2928 (2010); https://doi.org/10.1016/j.bmcl.2010.03.023.
  20. P. Jeffery, Phosphodiesterase 4-Selective Inhibition: Novel Therapy for the Inflammation of COPD, Pulm. Pharmacol. Ther., 18, 9 (2005); https://doi.org/10.1016/j.pupt.2004.09.027.
  21. J.M. O’Donnell and H. Zhang, Antidepressant Effects of Inhibitors of cAMP Phosphodiesterase (PDE4), Trends Pharmacol. Sci., 25, 158 (2004); https://doi.org/10.1016/j.tips.2004.01.003.
  22. D. Spina, The Potential of PDE4 Inhibitors in Respiratory Disease, Curr. Drug Targets Inflamm. Allergy, 3, 231 (2004); https://doi.org/10.2174/1568010043343822.
  23. P.M. O’Byrne and G. Gauvreau, Phosphodiesterase-4 Inhibition in COPD, Lancet, 374, 665 (2009); https://doi.org/10.1016/S0140-6736(09)61538-5.
  24. V. Sharma, S.R. Wakode, V. Lather, R. Mathur and M.X. Fernandes, Structure Based Rational Drug Design of Selective Phosphodiesterase-4 Ligands as Anti-inflammatory Molecules, Bull. Pharm. Res., 1, 33 (2011).
  25. FDA Approves Otezla to Treat Psoriatic Arthritis, U.S. Food and Drug Administration, 21 March 2014.
  26. FDA Approves Eucrisa for Eczema, U.S. Food and Drug Administration, 14 December 2016.
  27. S.L. Jin, S.L. Ding and S.C. Lin, Phosphodiesterase 4 and its Inhibitors in Inflammatory Diseases, Chang Gung Med. J., 35, 197 (2012).
  28. A.I. Vogel, Elementary Practical Organic Chemistry Part-1, Small Scale Preparations, CBS Publishers: London, edn 2, p. 363 (2004).
  29. O. Trott and A.J. Olson, AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization and Multithreading, J. Comput. Chem., 31, 455 (2010); https://doi.org/10.1002/jcc.21334.
  30. http://www.rcsb.org/pdb/explore/explore.do?structureId=3LY2.
  31. M.L. Zinovieva and P.G. Zhminko, Single and Repeat Dose Toxicity Study of 7-Hydroxycoumarin, Ethanol and Their Mixture in Rats, J. Pharm. Pharmacol., 5, 237 (2017); https://doi.org/10.17265/2328-2150/2017.05.002.
  32. S.K. Kulkarni, Handbook of Experimental Pharmacology, Vallabh Prakashan: New Delhi, edn 3, pp. 123-125, 128-131 (2004).
  33. A. Girdhar, S. Raheja, D. Pandita, V. Kharb and V. Lather, Synthesis, Docking, Characterization and Anti-Inflammatory Activity of Novel Phosphodiesterase-4 Inhibitors, Asian J. Pharm. Pharmacol., 4, 493 (2018); https://doi.org/10.31024/ajpp.2018.4.4.17.